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Defeating the trypanosomatid trio: proteomics of
the protozoan parasites causing neglected
tropical diseases
Anutthaman Parthasarathy a and Karunakaran Kalesh *b
Mass spectrometry-based proteomics enables accurate measurement of the modulations of proteins on a
large scale upon perturbation and facilitates the understanding of the functional roles of proteins in
biological systems. It is a particularly relevant methodology for studying Leishmania spp., Trypanosoma
cruzi and Trypanosoma brucei, as the gene expression in these parasites is primarily regulated by
posttranscriptional mechanisms. Large-scale proteomics studies have revealed a plethora of information
regarding modulated proteins and their molecular interactions during various life processes of the
protozoans, including stress adaptation, life cycle changes and interactions with the host. Important
molecular processes within the parasite that regulate the activity and subcellular localisation of its proteins,
including several co- and post-translational modifications, are also accurately captured by modern
proteomics mass spectrometry techniques. Finally, in combination with synthetic chemistry, proteomic
techniques facilitate unbiased profiling of targets and off-targets of pharmacologically active compounds in
the parasites. This provides important data sets for their mechanism of action studies, thereby aiding drug
development programmes.
1. Introduction
The protozoan parasites Leishmania, Trypanosoma cruzi and
Trypanosoma brucei, collectively known as the Tritryps, are the
etiological agents of the neglected tropical diseases (NTDs)
leishmaniasis, Chagas disease and human African
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trypanosomiasis, respectively.1 Collectively, these three diseases
account for the highest rates of mortality amongst all NTDs.2
The World Health Organisation (WHO) lists these NTDs in a
group of high priority diseases that require “innovative and
intensified disease management (IDM)” on the basis of several
factors including poorly understood disease burden, high
management cost, lack of appropriate control methods and
relatively low investment in research and development.2
Nevertheless, a 90% reduction in the number of African
trypanosomiasis cases has been noticed between 2009 and 2018
thanks to the coordinated efforts by control programmes in
endemic countries.3 However, a jump of over 26% in
leishmaniasis prevalence has been noticed between 2006 and
2016.4 NTDs caused by protozoans continue to be a growing
challenge since there is a shortfall in funding and development
in this field.5,6 Current treatment options, specifically in the case
of leishmaniasis and Chagas disease, are severely limited. For
instance, in Chagas disease, the only two available drugs,
nifurtimox and benznidazole, suffer from toxicity and limited
efficacy.7,8 Similarly, in the case of visceral leishmaniasis,
current front-line medications suffer from issues including high
cost, teratogenicity, drug resistance, requirement of non-oral
administration and prolonged treatment regimens, making
treatment in economically poor endemic areas particularly
difficult.9–11 There is an urgent need to develop new drugs that
can address these shortcomings of the existing ones. An
important step towards this goal is the identification and
validation of parasite proteins that can act as novel drug targets.
This is facilitated by modern proteomics studies that provide a
better understanding of the parasite proteome and its functions.
Despite the aforementioned difficulties, many recent
developments in the “omics” technologies are gradually
transforming the research landscape of NTDs caused by
protozoan parasites. The Human Genome Project not only
created opportunities to treat genetic diseases, but also
triggered the development of a number of sequencing
technologies such as ChIP-Seq and RNA-Seq, which are able to
provide detailed analyses of cell function.12 In general,
genomics and transcriptomic techniques allowed the
accumulation of large data sets and facilitated increased
understanding of the genetic aspects of diseases.13,14 Despite
all this promise, they have important shortcomings in the
investigation of disease states. Not all genes present in a
eukaryotic cell are expressed, since protein synthesis is
extensively regulated.15 mRNA levels are only an estimate of the
protein abundance and do not necessarily correlate with
protein expression.16 This is particularly relevant in the case of
Tritryps.17 These kinetoplastids are among the most
evolutionarily ancient eukaryotic lineages.18,19 However unlike
higher eukaryotes, gene expression in these parasites is almost
exclusively controlled by posttranscriptional mechanisms,
making DNA or mRNA-based analyses unreliable for protein
identification.20–22 An additional handicap is that genomic or
transcriptomic profiling cannot identify posttranslational
modifications (PTMs), which are often functionally critical.23
Understanding protein–protein interactions and protein
localisation is essential for obtaining a more complete picture
of cell function, but these issues cannot be addressed
satisfactorily by DNA or mRNA-based methods in the Tritryps.
Finally, DNA-based approaches cannot effectively answer
questions on gene function in systems where biological
information is lacking. For example, annotations of up to a half
of the open reading frames (ORFs) in Leishmania spp.
correspond to “hypothetical proteins”.24 Proteins are the
workhorses of the cell, which manifest the end stage of
regulation and drive both cellular structure and function, and
are thus critical for the understanding of complex processes
such as the development of diseases.
Proteomics, which is the systematic analysis of proteins, can
provide a more complete picture of global functional protein
expression in a cell, tissue or bodily fluid, giving a plethora of
information not accessible via other methods.25–27 While early
proteomics methods were developed for the characterisation of
a small number of proteins, later analytical advances allowed
the massive parallel detection and comparative studies of
thousands of proteins in a single mass spectrometry (MS)
run.28 Unlike earlier times, proteomics MS is now a genuine
hypothesis generation tool in conjunction with cellular,
molecular and pharmacological methods.29 Today, the
investigation of protein complexes and the characterisation of
protein pathways via MS methods have become commonplace.
More recently, RNA interference (RNAi) has emerged as a
common method to disrupt the synthesis of any protein
in vivo, offering the means to test the functions of proteins
identified by proteomics screens involving hundreds or
thousands of candidate proteins.30 However, in the field of
trypanosomatid parasitology, RNAi has only been used as a
genetic tool in T. brucei. Recent proteomic methods have also
enabled pathway analysis and have contributed greatly to
closing the gaps in knowledge generated by gene-based
methods.31 Consequently, they have facilitated the
identification of biomarkers, to support both diagnostics and
evidence-based drug design for disease models.32,33 The use of
proteomics, however, has its own limitations, especially with
respect to the reproducibility of label-free quantifications,
necessitating a sufficient number (often more than four) of
replications per experimental condition. Additionally, the
inherent bias of the MS technique towards abundant proteins
sometimes compromises sensitive detection and relative
quantification of low-abundant proteins.
This review is not meant to be an exhaustive survey of the
proteomics studies of the three protozoan parasites causing
NTDs. Instead, this review will highlight the key role that
proteomics has played as a particularly relevant technology for
shedding light on several aspects of the life process such as life
cycle differentiation, stress-adaptation, infectivity and drug
resistance of the Tritryps. An overview is provided in Fig. 1. It
will also cover important chemical proteomics approaches
applied to the three protozoan parasites for the target profiling
of pharmacologically active compounds and/or their
mechanism of action studies as well as the global profiling and
validation of therapeutically relevant PTMs in them.
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2. Proteomics approaches in
Leishmania
2.1 Leishmaniasis: an introduction
Leishmaniasis is a complex disease caused by about 20 species
of protozoan parasites of the genus Leishmania,34 which is
transmitted to humans via the bites of blood-sucking sandflies.
About 200 million people in over 90 countries in Asia, Africa,
Latin America and southern Europe live at the risk of exposure
to the parasite,35 with about 2 million new cases of
leishmaniasis and 20000–50000 deaths annually.34
Leishmaniasis affects mainly people experiencing poverty,
malnutrition, immune suppression, and pre-existing health
issues or people living in deforested areas undergoing rapid
urbanisation.34 The disease has three forms: cutaneous, muco-
cutaneous and visceral. While the other two forms are persistent
and disfiguring, visceral leishmaniasis causes significant
mortality and morbidity.35 Current Leishmania therapies are
largely inadequate. Only one antileishmanial compound,
miltefosine, is available for oral administration. The drug is,
however, a known teratogen and therefore unsuitable for use in
pregnant women.36 Other frontline treatments such as
amphotericin B (and its liposomal formulations) and
paromomycin require prolonged treatment regimens and are
Fig. 1 Overview of proteomics approaches in Tritryps. The proteome of each life cycle stage of a protozoan parasite of interest (Leishmania spp.,
Trypanosoma cruzi and Trypanosoma brucei) undergoes characteristic modulations as the parasite responds to a perturbation trigger. The
perturbation trigger can either be a natural factor that regulates the development of the parasite (such as changes in pH or temperature, variations
in availability of nutrients, and other environmental changes during its transition to a different host species) or a therapeutic intervention such as
an inhibitor/growth modulator treatment or a chemical probe treatment. The proteins extracted from a specific life cycle stage of the protozoan
parasite of interest following the perturbation window are typically digested to peptides using a protease such as trypsin. The proteomic samples
often require additional treatments such as reduction of disulphide bonds, alkylation of free thiols and extensive clean-up or desalting procedures.
The relative expression changes in several hundreds to thousands of proteins across different conditions are then measured with the liquid
chromatography-tandem mass spectrometry (LC-MS/MS) technique following a suitable quantitative proteomics approach such as label-free
quantification or one of the different types of label-based quantification methods. Processing, analyses and visualisation of the large proteomics
data sets are carried out using dedicated software programmes.
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unsuitable for administration in resource-limited endemic
areas.11,37 The old antimonial drugs suffer from widespread
resistance and are notorious for their toxicity.38 In general, all
currently available antileishmanials suffer from moderate to
severe toxicity, resistance and/or clinical relapse.10 Currently
there are no new therapeutics for leishmaniasis in clinical
development, and only a few in the preclinical stages.
Alarmingly, not only is there a scarcity of validated molecular
targets for drug development, but also a lack of knowledge on
the mechanisms of action of existing molecules approved for
clinical use. There is thus a dire need for new treatments,
particularly oral drugs, for visceral leishmaniasis.
2.2 The Leishmania life cycle
Leishmania spp. have a digenetic life cycle that alternates
between intracellular amastigotes in the vertebrate host and
multiple extracellular promastigote stages in the blood-
sucking sandfly vector. The growth cycle of the parasite in
the sandfly begins with weakly motile but highly proliferative
procyclic promastigotes in the midgut and culminates in the
non-dividing but strongly motile and infectious metacyclic
promastigotes. Once inside the vertebrate host, the
metacyclic promastigotes transform into non-motile
amastigotes, which replicate predominantly inside the
immune cells, especially macrophages. Amastigote
proliferation eventually leads to host cell rupture, allowing
entry into the host's blood stream and infection of other
phagocytes. The amastigotes in the host's bloodstream can
be taken up by another sandfly during its blood meal. In this
case, the amastigotes transform into procyclic promastigotes
in the sandfly's midgut, multiply by binary fission and
continue the life cycle.
2.3 Tracking variations in the parasite proteome for the
molecular characterisation of key life processes
In the early days of proteomics, the technique of choice for
proteome resolution was two-dimensional gel electrophoresis
(2-DE). This method allows separation of proteins in a cell
lysate according to their isoelectric points and molecular
masses. The resolved proteins are typically visualised by
protein staining, for instance by silver staining or by
Coomassie blue dye. The first report of Leishmania
proteomics employed 2-DE for revealing distinct protein
patterns between different L. tropica isolates causing simple
cutaneous leishmaniasis and those causing leishmaniasis
recidiva, a rare variant of cutaneous leishmaniasis.39 Later, in
order to gain insights into the molecular basis of the parasite
virulence in cutaneous leishmaniasis, protein patterns of
radiolabelled clones of infective and non-infective types
generated from a single isolate of L. tropica were compared.40
Although the observed protein patterns of the different
clones showed only minor differences, which could partly be
attributed to the limited sensitivity of the techniques
employed, this study showed the scope of using protein
profile differences to classify the infective and non-infective
Leishmania isolates. 2-DE proteome patterns have also been
demonstrated to be useful for highlighting the differences
between two different species of New World Leishmania (L.
mexicana and L. braziliensis) and for establishing relatedness
between subspecies.41
By the 1980s, the combination of 2-DE with MS gained
popularity. Several groups employed this combination for
gaining insights into the molecular mechanisms of
Leishmania differentiation. Nugent et al. used 2-DE to resolve
the proteome of axenically differentiated L. mexicana
parasites and observed about 2000 protein spots in the
different life cycle stages of the parasite.42 Several spots were
found to be life cycle-specific with the majority of unique
spots showing expression in the infective metacyclic and
amastigote stages. MS analyses of selected excised gel spots
led to the identification of 47 parasite proteins. Intriguing
findings include highly upregulated and preferential
expression of proteins involved in protein synthesis such as
eukaryotic translation elongation factor-1 alpha (eIF-1α),
eukaryotic initiation factor-5 alpha (eIF-5α) and 40S
ribosomal protein S2 after differentiation, as well as the
exclusive detection of certain heat-shock proteins (HSPs) (e.g.
HSP60 and HSP70) in the amastigotes.
As only the metacyclic form of the parasite infects
vertebrate hosts, some proteomics studies have focussed on
identifying the proteins that are differentially expressed in
this stage. Mojtahedi et al. employed the 2-DE–MS
combination for comparing the proteomes of L. major
procyclics and metacyclics.43 Consistent with the high
motility and arrested growth of the metacyclic parasites, they
observed an increased abundance of several proteins that
facilitate parasite motility, whilst the abundance of many
proteins involved in protein synthesis decreased. In a more
recent study, Moreira et al. applied a liquid-based free-flow
electrophoresis method for resolving the proteome of L.
infantum wild-type and a pteridine reductase 1 (PTR1) null-
mutant in the metacyclic and procyclic stages.44 The PTR1
null-mutant presented reduced levels of intracellular
tetrahydrobiopterin, an important growth factor for
Leishmania. A reduced level of pterins has been proposed as
one of the factors facilitating the metacyclogenesis. MS
proteomics revealed significantly altered expression of several
structural proteins and metabolic enzymes between the two
developmental stages in the contexts of both reduced and
normal pterin levels.
Many important molecular processes in the Leishmania
life cycle were revealed thanks to the development of axenic
promastigote cultures of the parasite. However, long-term
maintenance of the parasites in host-free cultures has been
shown to affect the infectivity and virulence.45 Nevertheless,
Leishmania axenic cultures also provide a convenient means
to generate drug resistant strains in the laboratory.46
Intuitively, the comparative proteomic study of a resistant
strain against its non-resistant counterpart could reveal
proteins associated with drug resistance. Walker et al.
applied this concept for deconvoluting the molecular factors
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associated with resistance to trivalent antimony treatment in
L. panamensis strains that were made resistant to the drug in
cultures.47 They have identified nine differentially expressed
proteins, which include stress-responsive proteins and
important metabolic enzymes S-adenosylmethionine
synthetase (SAMS) and S-adenosylhomocysteine hydrolase
(SAHH). Both SAMS and SAHH play key roles in the pathways
upstream of the biosynthesis of trypanothione, a unique thiol
metabolite of Kinetoplastida that is implicated in antimony
resistance and the parasite's response to oxidative stress.48,49
2.4 Application of quantitative proteomics MS in the study of
Leishmania parasites
Conventional 2-DE is now obsolete, with quantitative
proteomics MS techniques offering a far better sensitivity of
detection, the capability for high-throughput whole proteome
analysis in a single MS run and the quantitative comparison
of multiple experimental conditions in a single experiment.
Quantitative proteomics MS techniques are broadly divided
into label-free quantification (LFQ) methods, such as MS1-
intensity based methods50 and spectral counting-based
methods,51 and several different labelling-based methods.
Popular labelling strategies include TMT (tandem mass tag),52
iTRAQ (isobaric tagging for relative and absolute
quantitation),53 SILAC (stable isotope labelling by amino acids
in cell culture)54 and stable isotope dimethyl labelling.55
2.4.1 Study of host–Leishmania interactions. Today,
quantitative proteomics MS offers unprecedented capabilities
for correlating protein expression profiles with the
phenotypes of the parasites. It has now evolved as a robust
technology for identifying and differentially quantifying
virulence markers of different Leishmania species and strains,
enabling in-depth investigation of host–Leishmania
interactions. Rezende et al. used LFQ MS proteomics to
accurately capture the differential abundance of several
virulence factors of two different strains of the L. amazonensis
species, namely PH8 and LV79.56 They compared the lesion
development by the two strains in mice and observed that the
PH8 strain is the more virulent type. Additionally, lesion-
derived amastigotes from the PH8 strain were reported to be
more viable and more infective in vitro. LFQ comparison of
the lesion-derived soluble amastigote proteome of the two
strains revealed strikingly different protein abundance
patterns between them. The virulence factor GP63
metalloprotease was more abundant in the PH8 strain, whilst
virulence factors such as HSP70, tryparedoxin peroxidase,
superoxide dismutase and elongation factor 2, were relatively
more abundant in the LV79 strain. Menezes et al. applied
multidimensional liquid chromatography-tandem MS to
study the effects of Leishmania infection on a CBA murine
macrophage cell line resistant to L. major but susceptible to L.
amazonensis.57 They showed that the two different parasite
species differentially modulate several host-cell metabolic
proteins during the initial stages of Leishmania–macrophage
interaction. The differentially modulated metabolic proteins
identified are potentially the key drivers for the distinct
phenotypic macrophage responses observed (infection control
during L. major vs. parasite survival during L. amazonensis
infection). An iTRAQ quantitative proteomics study by Singh
et al. that compared the protein expression profiles of an L.
donovani infected THP-1 cell line also revealed the
modulation of several important host-cell metabolic pathways
including glycolysis and fatty acid oxidation.58 Another
important proteomic study shed light on the virulence
mechanism of the GP63 metalloprotease in Leishmania.59
Comparative proteomics of an immortalised murine bone
marrow derived Mφ LM1 cell line following infection with L.
major WT and L. major GP63−/− revealed extensive alterations
within the nuclear proteome of the host cell.59 Importantly,
the host cell nuclear protein pattern following infection with
L. major GP63−/− resembled that of non-infected cells,
indicating that the virulence mechanism of the GP63 protease
operates by modulating the host cell nuclear proteome.
Proteomics analyses of biological membranes is an
underrepresented area even though membrane proteins
constitute about 30% of a typical proteome.60 This is because
many membrane proteins tend to aggregate and precipitate in
the solution, making sample preparation notoriously difficult.
However, several membrane proteins have been implicated in
crucial roles in Leishmania–host interactions.61 Lynn et al.
isolated the membrane proteins of promastigote and
amastigote stages of L. mexicana and L. infantum parasites
using Percoll density gradients and profiled the differentially
expressed proteins using iTRAQ quantitative proteomics MS.62
They identified 107 L. mexicana and 189 L. infantum non-
redundant proteins, of which 20–40% showed significantly
different abundance levels between the two life cycle stages.
2.4.2 Profiling of the mRNA-bound Leishmania proteome.
As the gene expression in Leishmania is predominantly
controlled at the posttranscriptional level by mRNA
degradation and translation, efforts have been devoted to
profiling the mRNA-binding proteins (RBPs) of the parasite.
Towards this goal, Nandan et al. developed a workflow that
involves UV light-mediated covalent cross-linking of RBP to
mRNA in the live parasites followed by cell lysis and
capturing of the interactome using oligo(dT) magnetic
beads.63 The bound protein–mRNA complexes can be eluted
following RNase treatment and analysed by tandem MS.
Using this methodology, they identified 79 mRNA-binding
proteins in L. donovani axenic amastigotes. The majority of
the identified mRNA binders in this study had no
homologues or orthologues in humans, pointing to the
possibility that the data set may represent an important
resource for choosing selective drug targets in future drug
development programmes. de Pablos et al. recently adapted
this approach, combining it with LFQ proteomics MS for
profiling the mRNA-binding proteome of the different life
cycle stages of L. mexicana parasites.64 They observed a low
correlation of the protein expression with the transcript, and
parasite life cycle-dependent modulation of the mRNA-
binding proteome enrichment.
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2.4.3 Chemical proteomics in Leishmania. Chemical
proteomics is a rapidly growing interdisciplinary science that
uses synthetic chemical probes to understand protein
function.65,66 It enables the elucidation of the binding
engagements of pharmacologically active compounds with
their target protein(s) and facilitates their mode of action
studies. It also provides an alternative method to enrich and
characterise certain protein modifications, including PTMs,
for which conventional enrichment strategies often fail or
tend to be less effective. Another important capability of
chemical proteomics is the robust and unbiased global
profiling of substrates of PTM-generating enzymes and
shedding light on the modulatory effects of active/lead
compounds or drugs on these substrates in a high-
throughput manner. In the following section, we will discuss
some important findings on the Leishmania proteome
revealed by chemical proteomics methods.
2.4.3.1 Target fishing and mode of action studies.
Deconvoluting the mode of action of a pharmacologically
active chemical entity is a daunting task in drug discovery
programmes. A combination of complementary methods is
often required to identify the real target(s) and mode of
action. Wyllie et al. recently employed quantitative chemical
proteomics MS and in vitro evolution combined with whole-
genome analysis67 to identify cyclin dependent kinase 12
(CDK12) (also known as cdc-2-related kinase 12 or CRK12) as
the principal molecular target of their preclinical
pyrazolopyrimidine compound DDD853651 or GSK3186899
(compound 1 in Fig. 2) for visceral leishmaniasis.68 They first
developed a series of analogues (compounds 4–7, Fig. 2) of
DDD853651 with a polyethylene glycol (PEG) linker, which
after attaching to magnetic beads were used for competitive
chemical proteomic pulldown experiments. With compound
4 immobilised on beads, SILAC “light” and “heavy” labelled
L. donovani promastigote lysates were used for fishing out the
protein binders in the presence and absence respectively of
the structurally related competitive inhibitor compound 5.
This quantitative proteomics MS experiment identified
CDK12 along with several other cyclin-dependent kinases and
a few other proteins as selective binders of compound 4. A
second round of competitive chemical proteomics
experiments using the more potent inhibitors 2 and 3 as
Fig. 2 Leishmania CDK12 inhibitors and chemical probes from a pyrazolopyrimidine series used in the proteomics MS-based target profiling and
mode of action studies.68 Compound 1 (known as DDD853651 or GSK3186899) is a preclinical developmental compound against visceral
leishmaniasis. 2 is another potent compound with an aminopiperidine amide functionality. Compound 3 carries an isobutyl group and
2-methoxyphenyl group in place of the trifluoropropyl and 2-methylmorpholine groups in compound 1. Compounds 4 to 7 are structurally related
pyrazolopyrimidines with polyethylene glycol linkers. The primary amino groups in 4, 6 and 7 were used for immobilising the compounds on
magnetic beads, facilitating affinity enrichment of the protein binders of the compounds from SILAC-labelled parasite cell lysates, whereas
compounds 5, 2 and 3 were used as in-solution competitive binders of the proteins in the affinity-enrichment experiments.
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competitive binders, and beads derivatised with compounds
4, 6 and 7 also revealed a more or less similar set of selective
binders. They subsequently generated drug resistant strains
of the parasites and performed whole-genome sequencing,
which identified a key mutation in the catalytic site of the
CDK12 protein. Additionally, CDK12 overexpressing parasite
strains showed increased sensitivity to the compound,
indicating that CDK12 is indeed the principal target of the
pyrazolopyrimidine compound. In this case, the chemical
proteomics alone was not sufficient to identify the major
target of the compound. Nevertheless, it helped to narrow
down the likely candidates to a small set of proteins to
permit subsequent genetic target validation studies.
Thermal proteome profiling (TPP) and the related cellular
thermal shift assay (CETSA) are complementary to the chemical
probe-based target deconvolution methods.69–71 These are
based on the principle that binding of a ligand to a protein
target often increases the melting temperature (Tm) of that
protein. Therefore, when a drug-treated whole-proteome is
heated, unbound proteins may denature and precipitate while
the ligand-bound protein(s) remain in solution. Typically,
samples are treated to different temperatures and the soluble
portion of the proteome from each temperature treatment is
analysed by LC-MS/MS. It is often used in combination with a
quantitative proteomics MS method such as TMT labelling,
which permits the defining of the aliquot from each
temperature treatment using a specific isobaric label. The
target engagement of an N-myristoyltransferase (NMT)
inhibitor compound termed DDD1000097 in the L. donovani
promastigote proteome was recently unravelled using the TPP
method.72 Corpas-Lopez et al. treated L. donovani promastigote
lysates with DDD1000097 and the soluble proteome from the
aliquots heated to different temperatures was treated with
TMT-10plex labels.72 DMSO treatment instead of the inhibitor
treatment was used as a control. The data revealed the L.
donovani NMT protein as the most significant hit, with a 3.3 °C
increase in melting temperature (ΔTm) of the protein following
the inhibitor binding. Although currently limited to soluble
proteins, TPP and CETSA are useful proteomics methods for
the target deconvolution of non-covalent binders.
2.4.3.2 Global profiling of substrates of
N-myristoyltransferase in Leishmania. The enzyme NMT that
catalyses N-terminal myristoylation of glycine residues in
proteins is one of the few solidly validated druggable targets
in Leishmania.73 By using a terminal alkyne analogue of
myristic acid, Wright et al. metabolically labelled the
Fig. 3 Proteomics MS profiling of substrates of N-myristoyltransferase in (A) Leishmania donovani (promastigotes and amastigotes),74 (B)
Trypanosoma cruzi (epimastigotes, trypomastigotes and amastigotes)141 and (C) Trypanosoma brucei (bloodstream form).193
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N-myristoylome of L. donovani promastigotes and axenic
amastigotes.74 Affinity enrichment of the alkyne-modified
parasite proteins using a multifunctional capture reagent
exploiting the copperĲI)-catalysed azide–alkyne cycloaddition
(CuAAC) click reaction75 enabled LFQ proteomics MS
profiling of the parasite N-myristoylome (Fig. 3A). They
identified 113 and 49 myristoylated proteins in the
promastigotes and amastigotes, respectively. Intriguingly, the
majority of the identified proteins did not contain the
essential N-terminal glycine residue for N-myristoylation,
indicating that some of the observed modifications may have
a non-enzymatic origin and (or) that enzymes other than
NMT may have contributed to the observed labelling.
Therefore, in order to identify the specific NMT substrates in
the parasites, the researchers applied the metabolic labelling
approach in combination with a chemical knockdown of the
NMT protein using inhibitors. Although pre-incubation of
the parasites with the NMT inhibitors led to a reduction in
the fluorescent labelling, the LFQ proteomics experiments in
amastigotes did not reveal a uniform reduction of
myristoylation upon inhibitor treatment. However, a subset
of the enriched proteome (30 proteins in this study)
quantitatively responded to the NMT inhibitors. These
proteins all contain the N-terminal glycine residue, indicating
that they are substrates of the NMT enzyme in the parasite.
This highlights the power of chemical proteomics for
characterising the true substrates of an enzyme of potential
therapeutic relevance in the parasite.
2.4.3.3 Quantitative profiling of de novo protein synthesis in
Leishmania during starvation. Many studies point to the
adaptation of Leishmania parasites to nutrient scarcity as
playing potentially important roles in the differentiation
process.76–78 A method that could accurately and
quantitatively profile protein synthesis in the parasite during
a period of severe nutrient scarcity holds great potential for
elucidating the molecular processes facilitating adaptation to
such conditions. Towards this goal, we have recently
developed a methodology that combined the BONCAT (bio-
orthogonal non-canonical amino acid tagging) technology79
with iTRAQ quantitative proteomics MS in starving L.
mexicana promastigotes.80 In this approach, the methionine
surrogate, azidohomoalanine (AHA), was metabolically
incorporated into newly synthesised proteins (NSPs) of the
parasites subjected to nutrient deprivation for different
durations. Following cell lysis, the whole cell proteome from
each starvation window was separately subjected to click
chemistry using a biotin–azide capture reagent, which
enabled the selective tagging of the NSPs with biotin. The
biotinylated NSPs were affinity-enriched on streptavidin
beads, and after stringent washings, the bound proteins were
subjected to on-bead tryptic digestion. The tryptic peptides
from different starvation windows were labelled with
different iTRAQ labels and following the completion of the
labelling reactions, the samples were pooled together and
analysed by LC-MS/MS (Fig. 4). The multiplexed iTRAQ
approach enabled temporally resolved quantitative profiling
of over 250 starvation-specific NSPs in the parasite. This
study revealed a starvation-specific increase in the abundance
of several translation-regulating and stress-responsive
proteins, pointing to their important roles in the starvation-
adaptation of the parasite. Besides, this study provides a
robust methodology for analysing protein synthesis in the
parasite in a quantitative and temporally resolved manner.
3. Proteomics approaches in
Trypanosoma cruzi
3.1 Chagas disease: an introduction
Chagas disease (American trypanosomiasis) is caused by
Trypanosoma cruzi (T. cruzi) and is endemic in Latin America,
Fig. 4 Temporally resolved quantitative proteomics MS profiling of newly synthesised proteins in starving Leishmania mexicana parasites using a
BONCAT-click chemistry affinity enrichment-iTRAQ combination.80
RSC Medicinal ChemistryReview
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
M
ay
 2
02
0.
 D
ow
nl
oa
de
d 
on
 5
/2
6/
20
20
 9
:2
5:
00
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
RSC Med. Chem.This journal is © The Royal Society of Chemistry 2020
with a wide distribution of cases from the southern US to
northern Argentina.81 It is transmitted to humans via blood-
sucking triatomine bugs (or “kissing bugs”) and also spreads
by migration and blood transfusion.81 Early symptoms may
include fever, headaches, swelling at the bite site and lymph
node swelling. About one-quarter to a third of patients may
develop chronic infections. Some patients develop
enlargement of the heart ventricles, oesophagus or colon and
digestive or neurological complications up to 30 years after
the initial infection.82 Chemotherapy to treat Chagas disease
is reliant mainly on benznidazole (Bzn) and nifurtimox (Nx),
which were discovered over 40 years ago. They are efficient in
treating the acute phase, but of limited use in countering the
chronic phase. Both drugs have substantial side effects, need
long-term administration and are ineffective against diverse
strains, with certain strains being resistant to Bzn.83,84 Thus,
improved drugs, especially for the chronic stages, are an
urgent need. To make matters worse, only a few compounds
are in the clinical assay stage, although diverse natural and
synthetic compounds have in vivo and in vitro activity.
3.2 The T. cruzi life cycle
In the bloodstream of infected vertebrate hosts, T. cruzi exists
in a non-replicative trypomastigote form. When a triatomine
vector takes a blood meal from the infected host, the T. cruzi
in the blood meal transforms into the epimastigote form
inside the bug's midgut. The parasite then travels to the
bug's hindgut where it differentiates into infective metacyclic
trypomastigotes. When the infected bug takes a blood meal
again, it releases these infective trypomastigotes in its faeces
near the bite site. Once the trypomastigotes enter the
vertebrate host's cell, they differentiate into intracellular
amastigotes, which replicate by binary fission. The
amastigotes further differentiate into trypomastigotes and
enter the bloodstream. T. cruzi is considered a heterogeneous
species with a variety of strains in different vectors and
mammalian hosts, leading to a high variability in virulence.85
3.3 Characterising the life cycle stages of T. cruzi
The proteome mapping of T. cruzi has enabled the description
of stage-specific protein expression and led to the discovery of
some proteins responsible for drug resistance.86–88 In the
trypomastigote stage, the parasite relies more on glycolysis
than the mitochondrial electron transport chain to meet the
energy demand.89 Epimastigotes of the CL Brener reference
strain not only had elevated levels of tubulin and heat shock
proteins, which were present in multiple isoforms, but also
expressed arginine kinase, an enzyme not found in mammals,
thus presenting a potentially novel therapeutic target.90
Differential proteomic analysis led to the identification of 22
proteins, mostly metabolic proteins of the glycolytic pathway
(enolase, pyruvate kinase and 2,3-bisphosphoglycerate
mutase), along with cytoskeletal structural proteins,
polypeptide synthesis and chaperones/heat shock proteins.91
Antioxidant defence enzymes were implicated in drug
detoxification after prostaglandin F2α synthase was identified
as one of the proteins.92 The shotgun proteome of the blood
trypomastigote (BT) stage showed that the major groups were
trans-sialidase (TS), bioenergetics-related enzymes,
chaperones, and cytoskeletal proteins.93 Comparison of the
BT proteome with that of the tissue culture-derived
trypomastigote (TCDT) or metacyclic trypomastigote (MT)
demonstrated that over 2200 proteins were unique to the BT
stage and were involved in a variety of cellular processes.93
A large-scale comparative proteomic study showed that the
metacyclic form had the highest number of proteins
expressed, followed by amastigotes, epimastigotes and
trypomastigotes.86 The same study also reported that over a
third of the total proteome, accounting for over 1000
proteins, consisted of those annotated as “hypothetical”. One
notable observation was that the four stages of the parasite
might be characterised by distinct energy metabolites, such
as histidine during the insect stages and fatty acids during
the intracellular amastigotes in the mammal. Another study
based on only basic proteins found that epimastigotes may
use amino acid metabolism, but TS enzymes and flagellar
rod components were specific for trypomastigotes.94
Amastigotes also appeared to be rich in vesicular trafficking
proteins, and several important antioxidant enzymes such as
ascorbate peroxidase, mitochondrial tryparedoxin peroxidase,
trypanothione synthase and iron superoxide dismutase were
abundant in the metacyclic form, suggestive of parasite
anticipation of an oxidative attack by host phagocytes.86
Proteomic analysis of the trypomastigote stage identified over
1400 proteins, nearly 14% of which were mainly
glycophosphatidylinositol (GPI)-anchored surface proteins
that may be involved in host cell invasion and immune
evasion.95 Epimastigotes and trypomastigotes differed in over
50% of the expressed proteins according to one study, which
also identified some candidates with different isoforms
involved in metacyclogenesis.96
During metacyclogenesis, the proteome undergoes major
changes due to nutritional stress and at different time-points
after adhesion. A large-scale proteomic investigation led to
the observation of major differences in proteins involved in
oxidative stress, protein translation, and metabolic pathways
pertaining to proteins, lipids, and carbohydrates.97
Quantitative phosphoproteomic analysis in the same report
showed over 7000 phosphorylation sites, of which 260 were
regulated differentially, including some potential drug targets
such as the enzymes of sterol biosynthesis. A later study
reported that during nutritional stress, proteins with various
functions, such as fatty acid synthesis and regulation of
protein expression, were phosphorylated, which could in turn
trigger metacyclogenesis.98 The T. cruzi epimastigote enters
the stationary phase from the exponential phase, leading to
the early stages of metacyclogenesis. A proteomic comparison
of the exponential and stationary phases of epimastigotes
was able to quantify over 3000 proteins; ribosomal proteins
were upregulated in the exponential phase, whereas proteins
involved in autophagy were upregulated in the stationary
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phase.99 Further, the same report demonstrated the
regulation of proteins via N-terminal acetylation during this
transition from the exponential to the stationary phase.
The transition from trypomastigotes to amastigotes,
known as amastigogenesis, has also been investigated by
quantitative proteomics and phosphoproteomics approaches.
A number of proteins were regulated in this context, and the
majority of regulated proteins were membrane proteins.100
The differentiation of infective trypomastigotes to
epimastigotes is termed epimastigogenesis and is among the
least studied processes in the trypanosome field. An in vitro
method to generate epimastigotes revealed a previously
uncharacterised stage called the “recently differentiated
epimastigotes”, which resisted complement-mediated lysis
in vivo and in vitro.101 Later, proteomic studies identified
certain proteins, which were upregulated solely in the
recently differentiated epimastigotes, such as ABC
transporters and the multidrug resistance protein E.102
3.4 Study of host–T. cruzi interactions
The cell surface of T. cruzi features a dense layer of GPI-
anchored molecules, which mediate a variety of interactions
of the parasite with its insect vector and mammalian hosts. A
comparison of the cell surface proteomes during different
stages revealed that the majority of proteins are expressed in
more than one stage, but a few are stage specific.100 Further
analysis indicated that most of the proteins were membrane-
derived and could participate in invasion, adhesion, cell
signalling and modifying the host's immune response. The
proteomic analysis of membrane-associated fractions from
epimastigotes and MT stages showed that over 200 proteins
had predicted sites for post-translational lipid modifications,
signal sequences or transmembrane domains.103
Interestingly, the MT stage expressed a large set of surface
glycoproteins involved in host cell adhesion and invasion,
while epimastigotes did not.
T. cruzi is an intracellular pathogen and hence, adhesion
and invasion of the host cell are crucial processes.
Interaction with host cells involves both surface and secreted
molecules. Secreted molecules are known to play critical roles
in immune evasion, migration inside the host tissues, cell
adhesion, communication, differentiation, and parasite
proliferation.104 A novel family of surface membrane proteins
called TcSMP (T. cruzi surface membrane proteins) conserved
in different T. cruzi lineages has been characterised.105
Evidence suggests that the TcSMP are membrane-spanning
and might be released into the extracellular environment.
They were shown to bind mammalian cells, and trigger Ca2+-
dependent signalling and lysosome exocytosis, linking them
to host cell invasion. The secretome of T. cruzi consists of
extracellular vesicles and soluble proteins not associated with
vesicles.106 Metabolic proteins, as well as proteins implicated
in cell signalling, parasite survival, nucleic acid packaging
and virulence were detected by LFQ proteomics.106 The
exoproteome of the TCDT stage was characterised in the Y
strain as having 540 proteins; most were suggested to be
involved in host cell infections, implying that this parasite
has well-developed mechanisms to infect different types of
host cells and escape immune attack.107
Proteomics MS holds great potential for the discovery of
biomarkers for diagnostic purposes in Chagas disease. The
disease has a long incubation time extending to nearly three
decades, during which the amastigote forms remain in the
host. Therefore, identifying biomarkers derived from secreted
parasite molecules in the serum would improve the prospects
for a fast and reliable diagnostic assay. A comparative
proteomic analysis of the secretomes of two T. cruzi strains,
VD and CL Brener, revealed that over 350 of the proteins
could be classified into multigene superfamilies, but 94
proteins did not correspond to any known superfamilies.108
Since these proteins were not reported from other T. cruzi
strains, they could be potential biomarkers for infection by
either the VD or the CL Brener strain. Two other strains, Y
and YuYu, also showed distinct proteome profiles of the
released vesicles that could be correlated with differences in
their virulence and infectivity.109
Proteomics has also been employed for characterising the
immune complexome of T. cruzi-infected patients. In a
proteomic study on plasma from chronic Chagas disease
patients, Ohyama et al. identified 39 antigens derived from T.
cruzi and 114 autoantigens from the patients.110 In the same
study, more than half of all the patients carried the surface
protease GP63 and glucose-6-isomerase antigens derived from
the pathogen, as well as six human autoantigens, namely,
CD180 antigen, ceruloplasmin, fibrinogen beta chain,
fibrinogen beta chain isoform 2 preprotein, isoform gamma-
A of the fibrinogen γ-chain and serum paraoxonase.
Moreover, two factors, the human complement factor
H-related protein 2 and the TS of T. cruzi, occurred most
commonly in patients with symptomatic Chagas disease.
Another study characterised the absence of peptide fragments
of two proteins, apolipoprotein A-1 and fibronectin, in the
serum of patients successfully treated with Bzn for congenital
Chagas disease.111 Similarly, a proteomic study of two
Brazilian strains showed that the expression profiles differed
with respect to several proteins, including cruzipain, which is
a key virulence factor, and this could be correlated to
differences in infectivity determined through in vitro cell-
based assays.112 The use of antisense oligonucleotides
directed against TS, complement regulatory proteins or E64d
in order to inhibit the activity of the cruzipain was found to
be effective in reducing the virulence of a highly virulent
strain in mouse models.113
The virulence of T. cruzi strains varies widely, and the correct
identification of strains is beneficial for diagnostic and
treatment purposes. The typing of strains has been
accomplished by proteomic methods using tandem MS (MS/
MS) libraries.114 This method is independent of the genome
data. Moreover, this method reliably identifies the DTU strains
and is agnostic towards fragmentation techniques, gradient
lengths during chromatographic steps or variations in sample
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preparation. Immunology techniques have been combined with
proteomics in order to search for epitopes, which might propel
the development of vaccines. In such an immunoproteome
study, the calpain-like protein CAP5.5 was reported to be 23-
fold upregulated in the cardiac stage of Chagas disease,
compared to the asymptomatic stage.115 In addition,
immunoproteomics also led to the identification of the most
immunogenic parasite proteins in mouse serum as pyruvate
phosphate dikinase, Hsp-85, and β-tubulin. This work also
demonstrated that recombinant T. cruzi β-tubulin was sufficient
to immunize mice successfully against T. cruzi infection.116
3.5 Posttranslational modifications in T. cruzi
In addition to the protein phosphorylation PTM discussed
in section 3.3, several other PTMs have been characterised
by proteomics methods in T. cruzi. Selected studies are
reviewed herein.
3.5.1 PTMs of T. cruzi histones. Although the regulation of
gene expression in T. cruzi is predominantly
posttranscriptional, increasing evidence suggests that
epigenetic mechanisms also play a role in the parasite's life
processes.117 For functional epigenomic studies to be possible,
site-specific information on PTMs in the parasite histones
needs to be obtained. In a large-scale proteomics study, Picchi
et al. recently uncovered several PTMs including
unconventional modifications such as N-terminal methylation,
serine/threonine acetylation and non-canonical lysine
acylations in T. cruzi histones.118 This study also identified 200
unique conserved sites for PTMs on T. cruzi histones, thus
providing a data set that might prove useful for development of
epigenetic drugs in the future. Another study compared the
PTMs of histones in the epimastigote and trypomastigote
stages; epimastigotes exhibited more histone modifications
compared to trypomastigotes.119 Whereas in epimastigotes the
predominant modifications were phosphorylation at serine 23
of H2B and methylation of lysine 76 of histone H3, C-terminal
lysine acetylation of H2A and methylations of lysine 23 of
histone H3 were the major modifications in the MT and TCDT
stages. Owing to the importance of posttranslational histone
acetylation for the regulation of various aspects of the T. cruzi
cell cycle, the histone deacetylase inhibitor trichostatin A has
been used in a quantitative proteomic study.120 This study
showed that trichostatin A increases histone acetylation,
suggesting that histone deacetylase inhibitors could be
promising leads for drug development.
3.5.2 Protein glycosylation. Protein glycosylation, a
common PTM of cell membrane proteins, involves enzyme-
catalysed addition of carbohydrate moieties to protein
molecules. It may range from simple monosaccharide
additions to highly branched complex polysaccharide
modifications. The nature of the carbohydrate–amino acid
chemical bond classifies the modification; the two major
types are the N-linked and the O-linked glycosylations, which
respectively feature the bonding of the carbohydrate moiety
with the side-chain amide nitrogen atom of an asparagine
residue and the side-chain hydroxyl oxygen atom of a serine/
threonine residue. Glycoproteins participate in many
important processes of the parasite life cycle including host
cell adhesion and invasion, and evading host immune
responses.121,122 Therefore, they are considered promising
drug targets in Chagas disease. Atwood III et al. performed
affinity enrichment of N-linked glycoproteins from T. cruzi
trypomastigotes using lectin columns.123 They used a
combination of subcellular fractionation, stable isotope
labelling of the glycan attachment site using H2
18O and LC-
MS/MS to identify 36 N-glycosylation sites in 29 parasite
proteins, of which 11 were T. cruzi-specific. A more recent
comprehensive glycoproteomics study employed glycanase
treatment to identify 170 glycoproteins specific to the
epimastigote stage, and 334 proteins specific to the
trypomastigotes.124 Further, when the glycanase treatment
was omitted and intact glycopeptides were analysed, 144
N-linked members and 10 O-linked peptides were unique to
epimastigotes, while for trypomastigotes the numbers in the
same categories were 466 and 97. It is likely that these stage-
specific changes reflect the switching between invertebrate
and vertebrate host cells during the life cycle.
Modification of the hydroxyl side chain of serine/threonine
residues with a single unit of β-N-acetylglucosamine, termed
O-linked β-N-acetylglucosamine (O-GlcNAc) modification, has
been implicated in many important cellular processes including
the regulation of transcription and translation in higher
eukaryotes.125 The O-GlcNAc modification is fundamentally
different from other types of glycosylation: whereas the
common N- and O-glycosylations are relatively stable PTMs, the
O-GlcNAc PTM is dynamic. It is catalysed by the enzyme
O-GlcNAc transferase (OGT) and removed by N-acetyl-β-D-
glucosamidase (O-GlcNAcase). In a recent study, Torres-
Gutiérrez et al. reported the identification of the O-GlcNAc
modification in T. cruzi proteins.126 They used the commercial
“Click-iT O-GlcNAc enzymatic labeling system”127 for
enzymatically labelling and enriching the O-GlcNAc modified
proteins from T. cruzi epimastigote lysates. On-bead digestion
using a trypsin/Lys-C mixture followed by LC-MS/MS analysis of
the eluted peptides identified 1271 putative O-GlcNAclated
proteins. As the on-bead digestion protocol led to the retention
of O-GlcNAc modified peptides on the resin, on-bead
dephosphorylation and β-elimination steps prior to protein
digestion were performed on a separate portion of the sample
to release the modified peptides. This enabled the identification
of six O-GlcNAc modification sites. Many of the putative
O-GlcNAclated proteins identified have important biological
roles including metabolic functions and stress adaptation.
3.5.3 SUMOylation. SUMOylation is a PTM that involves
covalent attachment of small ubiquitin-like modifier (SUMO)
proteins to other proteins via an isopeptide bond between a
newly exposed C-terminal glycine residue of SUMO and side-
chain amino group of lysine residues of acceptor proteins. It
is a dynamic PTM and relies on the enzymes of the ubiquitin
activating, conjugating, and ligating cascades for its
formation and ubiquitin deconjugating enzymes for reversal.
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Despite the similarity with ubiquitination and reliance on the
ubiquitination machinery, SUMOylation is not used as a
protein degradation signal. Instead, a broad spectrum of
cellular processes including transcription, nuclear–cytosolic
transport, DNA damage responses, protein localisation and
protein–protein interactions are influenced by
SUMOylation.128 Using transgenic T. cruzi epimastigotes
expressing a SUMO version with purification tags of human
influenza hemagglutinin (HA) and hexahistidine (His6),
Bayona et al. reported the first proteomics study of
SUMOylation in T. cruzi.129 The presence of the two
purification tags allowed a tandem affinity enrichment of the
SUMOylated proteins from the parasite lysate using Ni2+-NTA
and anti-HA–agarose columns. Analysis of tryptic digests of
the final eluents via two-dimensional LC-MS/MS revealed a
total of 236 putative SUMOylated proteins. Nonspecific
binding interactions, despite the use of tandem affinity
purification, the lack of identification information about the
modification sites and the lack of availability of a specific
inhibitor compound for control experiments, make the
validation of putative SUMOylation targets difficult.
Nevertheless, independent biochemical assays validated
metacaspase-3 from the putative target list as a genuine
substrate of SUMOylation in the parasite.
3.6 Protein–protein interactions in T. cruzi
The combination of proteomics with an assessment of
protein–protein interactions, termed “interactomics” forms
part of a powerful approach to understanding cellular
processes.130 The construction of mutant redox proteins and
proteomics of the resulting complexes from pull-down assays
with T. cruzi lysates have been used to identify proteins
interacting with two major redox enzymes, tryparedoxins I
and II (TcTXNI and TcTXNII).131,132 According to these
studies, TcTXNI had 15 interacting protein partners, mainly
with roles in redox metabolism and protein synthesis/
degradation, and TcTXNII had 16 partners involved in a
variety of cellular functions. These two enzymes transfer
electrons between trypanothione and peroxiredoxins, which
is different from the thioredoxin-based electron transfer in
mammals and may present novel targets for drug
development.133 More recently, two TcI strains of T. cruzi,
COL and SYL, were analysed by proteomics, which showed
that the antioxidant network of the trypomastigotes was
enhanced in comparison to that of a cultured clone.134
3.7 Chemical proteomics in T. cruzi
3.7.1 Target fishing and mechanism of action studies. The
mechanism of action of benznidazole (Bzn), the major drug
used in the treatment of Chagas disease, remain elusive. In
order to identify the protein binding partners of the drug,
Trochine et al. used a chemical proteomics approach.135 They
first synthesised a Bzn derivative and immobilised that onto
sepharose beads, which was then used for affinity
chromatography with T. cruzi epimastigote lysates. The
affinity-enriched proteins were resolved on a 1D gel and
selected protein bands after tryptic digestion were analysed
by MALDI-ToF/ToF MS/MS. A total of six proteins namely
protein transport protein Sec23A, YXKO-related protein,
α-tubulin, β-tubulin, β-tubulin 1.9 and T. cruzi aldo–keto
reductase (TcAKR) were identified. As TcAKR is related to
enzymes previously reported to be associated with Bzn
reductive activation, such as T. cruzi nitroreductase
(TcNTRI)136 and T. cruzi prostaglandin F2α synthase/old
yellow enzyme (TcOYE),137 the study points to the possibility
of reductive activation pathways for the drug action.
However, the lack of competitive binding controls in this
study makes arriving at definitive conclusions regarding the
mechanism of action difficult. Resistance to Bzn has also
been investigated by proteomics, leading to the identification
of overexpressed proteins in one clone as calpain-like
cysteine peptidase, hypothetical protein conserved 26 kDa,
putative peptidase, peroxiredoxin, and tyrosine amino
transferase, and in another as cyclophilin A, glutamate
dehydrogenase, iron superoxide dismutase, and nucleoside
diphosphate kinase.87
Napthoimidazoles derived from β-lapachone were shown
to induce changes in the expression of a number of proteins
in bloodstream trypomastigotes, including enzymes such as
asparagine synthetase, arginine kinase, enolase, guanine
deaminase, succinyl-CoA ligase, ATP synthase subunit B,
and methionine sulfoxide reductase, thus paving the way for
target-based drug design.138 In epimastigotes, proteomic
methods allowed the elucidation of the mechanism of
trypanocidal action following napthoimidazole treatment.88
Several pathways impacted were identified in this work,
including energy metabolism, protein biosynthesis,
chaperone modification, cytoskeletal assembly and
ergosterol biosynthesis. Proteomics has also facilitated the
study of the possible mechanism of action of trypanocidal
natural products. For instance, following piplartine
treatment, the expression of two antioxidant enzymes,
tryparedoxin peroxidase (TXNPx) and methionine sulfoxide
reductase (MSR), was upregulated in T. cruzi, suggesting that
these enzymes could be potential therapeutic targets.139
3.7.2 Global profiling of substrates of NMT in T. cruzi.
NMT inhibitors have been shown to inhibit the growth of T.
cruzi parasites.140 Additionally, these inhibitors caused a
dose-dependent decrease in the metabolic incorporation of
an azide analogue of myristic acid into the myristoylome of
the parasite.140 Roberts et al. recently extended this metabolic
incorporation approach by combining it with LFQ- and
SILAC-based quantitative proteomics MS in the presence and
absence of their NMT inhibitor compound DDD85646.141
Their analyses identified 50 N-myristoylated proteins in T.
cruzi, representing ∼0.43 to 0.46% of the parasite's total
known proteome (Fig. 3B). Although the majority of the
identified NMT substrates had unknown functions, a few
proteins from the data set have important biological roles
including intracellular transport, protein turnover and cell
signalling.
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4. Proteomics approaches in T. brucei
4.1 Human African trypanosomiasis: an introduction
Human African trypanosomiasis (HAT), also known as
African sleeping sickness, is caused by protozoa of the
species Trypanosoma brucei (T. brucei). The disease is endemic
in sub-Saharan Africa where it mainly affects poor rural
communities; about 55 million people are at risk of
contracting it.142 T. b. gambiense accounts for the vast
majority of cases of HAT in West and Central Africa, while T.
b. rhodesiense accounts for the rest, mainly in East and
Southern Africa.142 HAT is transmitted to humans via the bite
of tsetse flies (Glossina), whereupon the parasites multiply
and invade the blood and lymphatic system. The T. b.
gambiense variant causes a slow-developing chronic disease
in two stages; stage 1 (S1) is the hemolymphatic stage
involving fever, headaches, inflammation of the lymph
nodes, and simultaneous spleen and liver enlargement.143
Progression to stage 2 (S2), the nervous stage, is characterised
by invasion of the central nervous system and neurological
symptoms, which can lead to death.144,145 Patients with T. b.
gambiense infections in S1 respond to pentamidine, but S2
patients need drugs that can cross the blood–brain barrier.
S2 infection can be treated with a nifurtimox–eflornithine
combination therapy (NECT) by invasive methods, which are
challenging to execute in some areas.146 Both stages can be
treated by fexinidazole, which was approved last year.147
However, accurate diagnosis of the stage of HAT will save
lives and will need further research. For HAT infection
caused by T. b. rhodesiense, only one drug, melarsoprol, is
currently available.148 Development of more oral drugs will
benefit the efforts to eliminate both forms of HAT.
4.2 The T. brucei life cycle
Inside the gut of the tsetse flies, the parasites exist as
procyclic trypomastigotes and multiply by binary fission.
When leaving the midgut, they differentiate into
epimastigotes and migrate to the salivary glands, where a
further differentiation to a metacyclic trypomastigote form
occurs. When the vector bites the victim, the metacyclic
trypomastigotes enter the human bloodstream and
transform into bloodstream trypomastigotes, which rapidly
multiply by binary fission, and reach various body fluids
such as the spinal fluid and the lymph. In the
bloodstream, the trypomastigotes proliferate in a long
slender (LS) morphological form, which further
differentiate, as the parasite-load in the bloodstream
increases, into a short stumpy (SS) non-replicative form.
The replication arrested SS forms are adapted for
transmission to the tsetse flies, where they transform into
procyclic promastigotes and continue the life cycle. The
LS forms are responsible for the neurological
complications arising in S2 of HAT. During this multi-
stage life cycle, the parasite adapts by varying its
proteome.149–151
4.3 Characterising the life cycle stages and host–T. brucei
interactions
Global proteome profiling of procyclic and bloodstream
stages of T. brucei with SILAC quantitative proteomics MS
revealed that the procyclic forms have slower proteome
turnover compared to the bloodstream stage; the fastest
turnover rates were observed for cell cycle and cytokinesis
proteins in both forms.152 Further, lower than average
turnover rates were observed for mitochondrial and
glycosomal proteins.152 Quantitative SILAC-based proteomics
also helped to uncover the stage-specific expression of many
proteins, for example, a DEAD box RNA helicase was found to
be highly upregulated in the bloodstream form and is thought
to be critical for parasite viability and cell cycle
progression.153 SILAC-based proteomics MS also showed
remodelling of the proteome during three different human-
infective forms and the final procyclic stage, with almost 30%
of the proteome undergoing changes.154 More specifically,
about 40% of the proteins in the plasma membrane,
peroxisome, nucleus, mitochondria, microtubule, lysosome
and glycosome are upregulated by 2-fold or more while
differentiating to the last bloodstream stage (short stumpy or
SS). Quantitative proteomics enabled the tracking of over
4000 proteins during this transition and offered clues on how
the parasites might evade host defence mechanisms.150
Evasion of the mammalian host immune defence is
dependent on the antigenic variation of the variant surface
glycoprotein (VSG).155 In the bloodstream form, the parasite
surface is covered with around ten million copies of a single
species of VSG and the sub-telomeric VSG genes are the major
virulence determinants. The transcription of VSG at any time
occurs from only one of the 20 sub-telomeric expression sites
with switching to avoid lysis by the host adaptive immune
response. Regulation of virulence gene expression by telomere
structures is known in microbial pathogens, wherein those
genes are often located next to the telomere.156 Differentiation
of the bloodstream form into the procyclic form silences the
transcription of the VSG genes. MS of the telomere protein
complexes revealed that the complex composition differs
between the two forms of the parasite.157 One novel telomere-
associated protein, TelAP1, forms a complex with other
telomeric proteins and participates in expression site
silencing. Metabolomics studies have revealed that the
myristate required for incorporation into the VSG can be
synthesised by up to four distinct pathways.158 Indeed,
multiple redundant biochemical pathways are used by many
pathogens, and proteomics may help uncover which pathways
and enzymes are involved in each stage.
In combination with subcellular fractionation techniques,
proteomics enables biochemical characterisation of subcellular
organelles. A nuclear proteome study of T. brucei in the
procyclic form has demonstrated that over 750 proteins
specifically enriched in the nuclear fraction.159 Motif
enrichment analyses detected the presence of the KRxR
sequence in many of these identified nuclear proteins, which is
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proposed to be the nuclear localisation signal for the
Kinetoplastida class. Studies have also been carried out for
characterising the proteome of the T. brucei lipid rafts.160,161
These are regions of the plasma membrane with high
concentrations of cholesterol and glycosphingolipids and are
postulated to be hubs that cluster virulence factors.162 The lipid
raft proteome of the procyclic form contains proteins, of which
functions of around 18% remain unknown.161 In addition,
proteins with known or predicted functions also occurred,
including Rab-like GTPases (part of the intra-flagellar transport
protein or IFT complex), aquaporin, arginine kinase, and
calcium dependent cysteine proteases.161 Arginine kinase is a
flagellar protein, which plays an important role in infection,163
while aquaporin is a water channel protein which may also
transport drugs, localising to the plasma membrane and
implicated in the pentamidine resistance of the bloodstream
form.164,165 A remarkable 60% of proteins are shared between
the procyclic lipid raft proteome and the procyclic flagellar
proteome.161 Superoxide dismutase (SOD), a glycosomal
protein, was also found in the lipid raft. While its role in T.
brucei is not yet elucidated, overexpression of the T. cruzi
homologue causes enhanced susceptibility to the drugs Bzn
and gentian violet in that organism.166
The potential number of coding sequences in the T. brucei
genome is greater than previously thought; a transcriptomic
study identified over 1100 sequences under 100 amino acid
long, which map onto regions of the genome not containing
annotated ORFs.167 Although 993 of these transcripts contain
coding sequences corresponding to at least 25 amino acids,
their functional expression remained unknown. Nevertheless,
a combined application of bioinformatics methods and
analysis of previous proteomics data sets successfully
identified with high confidence 42 of these small proteins.167
More recently, Crozier et al. employed TMT-10plex
quantitative proteomics MS for the analysis of the cell cycle
of the procyclic form of T. brucei.168 They quantified the
expression levels of over 5000 proteins across the cell cycle in
the parasite. Off these, 384 proteins showed cell cycle
regulated patterns of expression; 151 of these were
hypothetical proteins of unknown function. About 40 of these
are considered critical proteins for the parasite survival and
therefore could be potential drug targets.
Using proteomics, over 60 human proteins were identified
to vary in abundance in the serum, cerebrospinal fluid (CSF),
urine and saliva between T. brucei-infected and healthy
subjects.169 Two of them, neuroserpin from the CSF and
moesin from urine, are considered potential biomarkers for
HAT.169 Neuroserpin is predominantly expressed in regions
such as the hippocampus and the caudate.170,171 Both those
regions are near the choroid plexus, which constitutes a gap
in the blood–brain barrier, and is suggested to be the site
where the parasite enters the brain.172
Proteomic comparisons of infected and uninfected salivary
glands of tsetse flies revealed that highly abundant G.
morsitans proteins were downregulated in infected salivary
glands.173 If this affects fly performance, it could lead to
increased transmission, since it is known that when fly
feeding is reduced, biting behaviour increases in order to
reach satiety.174 In addition, other proteins advantageous to
T. brucei were upregulated, including CamK, Serp-2, SUMO,
eight distinct V-type ATPases and amino acid metabolism-
related proteins.173 CamK is a key regulator of stage-specific
morphological differentiation in all parasitic protozoans,175
while Serp-2 plays a role in Plasmodium parasites to trigger a
switch to transmissible sexual stages in mosquitoes.176
SUMO, responsible for SUMOylation discussed earlier in
section 3.5.3, provides a quick way for changing the
interaction partners and subcellular localisations of proteins,
thus contributing to immune evasion.177 Downregulation of
regulatory proteins occurred along with upregulation of the
ubiquitin proteasome components, suggesting that protein
translation/turnover increases leading to metacyclogenesis.173
Among proteins specific to T. brucei, suppression of
regulatory proteins and transporters, and the upregulation of
a high number of immunity, signal transduction and
virulence-related proteins were observed.
4.4 Proteomics of the T. brucei flagellum
T. brucei is an extracellular parasite and all endocytosis and
exocytosis are directed through a specific membrane region
called the flagellar pocket, in which the majority of invariant
surface proteins are considered to be localised.178 Genome
mining for proteins with membrane-association is of limited
utility since a large number of the predicted proteins are not
likely to be surface-localised. A combination of biochemistry,
proteomics and bioinformatics was used to characterise the
surface proteome, which contained novel proteins, known
flagellar pocket proteins and proteins required for parasite
survival.179 Transporter-like proteins in the parasite were
conserved in well-studied eukaryotes, but receptor-like proteins
were mostly specific to trypanosomes. While the said study was
able to support the view of a three-compartment cell surface, the
mechanisms of protein sorting and targeting are still unclear.
No simple localisation signals were found, and the protein
architecture type did not correlate with domain localisation.
The flagellum plays important roles in T. brucei cell
motility, parasite signalling and development, and parasite
attachment during invasion of the salivary glands of the
tsetse fly, but a sensory role has also been postulated.180
Proteomic analysis of the intact flagellum detected over 200
proteins not previously linked to flagella; out of these, a 14-3-
3 protein and eight novel proteins termed FLAM (flagellar
member) were experimentally validated.181 Cardiolipin is a
mitochondrial and bacterial lipid important for the stability
of electron transport complexes.182 Unlike other eukaryotes,
the Apicomplexa (which include the malaria parasites) and
the Euglenozoa (which include the trypanosomatids) harbour
bacterial-type cardiolipin synthases.183 This difference
between T. brucei and its hosts, and the fact that it is
essential in T. brucei make cardiolipin synthesis an attractive
target for therapeutic interventions. Combining the use of
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knockout mutants for cardiolipin synthase, SILAC and MS, a
number of proteins that bind cardiolipin, termed cardiolipin-
dependent proteins (CLDP), were discovered.184
4.5 The phosphoproteome of T. brucei
Global phosphoproteomics in T. brucei enabled quantitative
comparisons between the procyclic and bloodstream forms
and revealed significant differences in phosphorylation
patterns between the two forms.185 In the procyclic form, a
number of proteins exhibited upregulation of specific
phosphorylation sites, including a C14-sterol reductase
involved in ergosterol synthesis, a ubiquitin carboxy-terminal
hydrolase and PAD2, a carboxylic acid transporter with
possible roles in cell differentiation. The bloodstream form
upregulates the phosphorylation of other proteins, for
example, the RNA recognition motif protein RBP10, which
could promote bloodstream mRNA expression. Certain
groups of proteins such as ZFPs (zinc finger proteins) and
RBPs (RNA binding proteins) which are expected to
participate in the posttranscriptional regulation of gene
expression were also subject to regulated phosphorylation.
Tyrosine-specific phosphoproteomics in T. brucei procyclic
forms using a combination of immunoaffinity purification
and LC-MS/MS identified over 30 tyrosine-specific
phosphorylated proteins involved in protein synthesis, RNA
metabolism, energy metabolism, and kinases, including 19
protein kinases and two metabolic kinases.186 In the CMG
kinase group, 11 candidates were found to be putative
homologues of Leishmania MAPK (mitogen-activated protein
kinase). The highly conserved TXY motifs in the activation
loops were found fully phosphorylated in eight of the
putative TbMAPKs, suggesting that they were activated in the
procyclic form of T. brucei.186 The phosphoproteome of the
bloodstream form showed that phosphorylated serine/
threonine kinases (STE kinases) were present, suggesting
signal transduction via MAPK.187 Moreover, the same study
indicated that phosphorylation of certain proteins is not
stage-specific, since all three CRK isoforms were
phosphorylated on the same tyrosine residue. Tyrosine-
phosphorylated proteins in both bloodstream and procyclic
forms were concentrated in the nucleolus and the
cytoskeletal structures (basal body and flagellum), lending
support to the notion that the function of signalling
molecules is governed by their subcellular localisation. The
localisation pattern also underscores the differences between
this parasite and higher eukaryotes, such as humans, since
kinetoplastids are among the most ancient eukaryotes,
probably older than even fungi.19 Further, the localisation of
glycogen synthase kinase 3 (GSK3) in the flagellum, along
with identified phosphorylation sites in its active loop,
indicates that this kinase is active in T. brucei, and suggests
that tyrosine phosphorylation may participate in the
regulation of flagellum formation and basal body
segregation.187 In fact, many organelles such as the basal
body, the flagellum, the mitochondrion and the kinetoplast
(mitochondrial DNA network) are present in a single copy
and must be segregated and duplicated during cell division.
Therefore, understanding organelle segregation and
duplication could be important for drug development.
Tyrosine-phosphorylated GSK3 has been previously shown
to be essential for flagella assembly and maintenance in
Chlamydomonas reinhardtii.188 Therefore, GSK3 possibly plays
a similar role in T. brucei. The T. brucei genome lacks tyrosine
kinase-like kinases, G protein-coupled receptors and proteins
with phosphotyrosine-binding domains, but phosphorylation
of the members of the STE kinase family and a homologue of
the ERK1 from the amoeba Dictyostelium discoideum indicates
the presence of a putative ERK1/2 signalling pathway in T.
brucei.187 The mechanism or regulation is still unknown and
likely novel. Additionally, about a quarter of the manually
validated kinase sites were not predicted by bioinformatics,
suggesting that T. brucei may contain kinases with novel
substrate specificity and previously unrecognised motifs.187
4.6 Chemical proteomics in T. brucei
4.6.1 Target profiling of oxaboroles. The oxaborole
compound SCYX-7158 is currently in clinical trials in patients
with S1 and S2 HAT caused by T. b. gambiense.189 However, its
mechanism of action remains unknown. Jones et al. employed
a chemical proteomics approach for identifying the target
proteins of the drug that could be involved in the mechanism
of action.190 They first synthesised an oxaborole derivative
and immobilised it onto paramagnetic beads for performing
target-fishing experiments. In one set of experiments, SILAC
heavy and light isotope labelled T. brucei cell lysates were
incubated with the beads in the presence and absence
respectively of the parent oxaborole inhibitor pre-incubated in
the lysate. As the dissolved inhibitor compound in the lysate
may outcompete target engagementĲs) of the immobilised
compound, specific targets may produce a lowered heavy/light
ratio whilst that of the non-specific binders remains
unaffected. In a second set of experiments, inactive beads
without the oxaborole immobilisation were used as a control
against the oxaborole-immobilised beads for pull-down
experiments using SILAC heavy and light isotope labelled
lysates, respectively. In this case also, the non-specific binders
may remain unaffected by the SILAC and may generate a log2
(heavy/light) ratio of zero, whilst that of the specific binders
may be less than zero. By comparing the results from the two
approaches, they identified 13 common proteins that
generated more than four-fold selectivity against non-specific
binders, indicating polypharmacology for the oxaborole
activity. Among the identified proteins were metabolic
proteins involved in glycolysis, the tricarboxylic acid cycle,
gluconeogenesis, proteolysis and branched chain amino acid
metabolism, as well as hypothetical proteins and proteins
linked to mRNA splicing and mitochondrial biogenesis. This
coupled with the difficulty in generating resistant mutants
strongly suggested that the mechanism of action is not
specific to one target (polypharmacology).
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4.6.2 N-Terminal myristoylation. A landmark study of
Frearson et al. validated T. brucei NMT as a promising
therapeutic target for HAT.191 Later, by using an alkyne-
tagged myristic acid analogue, Price et al. developed a
metabolic labelling approach for assessing N-myristoylation
of a small GTPase protein T. brucei Arf-like protein 6
(TbARL6).192 In this case, a click reaction with a fluorescent
azide dye permitted in-gel fluorescence imaging of the
labelled TbARL6 protein, confirming its myristoylation.
Wright et al. extended this metabolic tagging approach by
combining it with LFQ proteomics MS in both insect and
bloodstream stages of the parasite (Fig. 3C).193 The study
identified 91 and 101 putative N-myristoylated proteins in the
insect and bloodstream stages, respectively. Approximately
half of the identified proteins possessed the N-terminal
glycine residue or “MG signature motif” required for the
NMT-mediated myristoylation. The non-MG enriched
proteins were predominantly GPI-anchored and S-acylated
(e.g. palmitoylation at cysteine residues). In the bloodstream
parasites, NMT inhibitor treatment specifically reduced the
incorporation of the alkyne myristic acid analogue into the
NMT substrates but not the GPI-anchored proteins, clearly
indicating the target specificity of the inhibitor.
4.7 Nascent DNA proteomics
The trypanosomatids exhibit unusual DNA replication
properties, such as highly divergent origin replication complex
(ORC) subunits, an apparent absence of many replication factor
homologues and considerably fewer origins of replication than
well-studied eukaryotes.194,195 The application of iPOND
(isolation of proteins on nascent DNA) technology to T. brucei
identified proteins involved in the core replication machinery,
transcription, chromatin organisation, and DNA repair that
were enriched near an unperturbed active replication fork.
About 100 of those proteins were annotated as performing
“unknown functions” and potentially specific to trypanosome
replication. Follow-up studies on two proteins annotated as
Tb927.10.7990 (replication factor C subunit) and Tb927.3.5370
(protein of unknown function) revealed that Tb927.10.7990 is
essential since its silencing resulted in a growth defect in
procyclic cells. Apart from antigenic variation, unusual
replication and posttranscriptional regulation, trypanosomes
also display other features such as polycistronic transcription
without classical promoters and transcription of certain
abundant proteins by RNA polymerase I, underlining the
importance of unique nuclear processes in their biology.
5. Conclusions
Mass spectrometry-based proteomics has evolved as a powerful
technique for studying various aspects of the life cycle of the
protozoan parasites causing NTDs. The lack of transcriptional
control of gene expression in Tritryps makes protein-based
functional studies particularly suitable in these organisms. The
differentiation process or life cycle changes is a peculiar aspect
of the protozoan biology, the molecular mechanisms of which
are largely unknown, despite decades of research using
conventional methods of parasitology or biological research
methods in general. Unravelling the molecular processes
associated with life cycle differentiation holds the keys to
understanding the mechanisms of virulence and infectivity.
Proteomics MS has so far facilitated the measurement of the
differential expression of several hundreds of proteins during
the various life cycle stages of the three parasite genera reviewed
herein. It is generally assumed that protein interactions in the
differentially modulated proteomes detected in the life cycle
stages are responsible for the observed phenotypic changes.
Deconvoluting the molecular interactions and accurately
annotating their functions within the modulated proteome will
take significant in silico studies and follow-up biochemical
experimental studies. However, a caveat is that the original
measurements of the proteome were not made in real-time, as
in during the transition of one life cycle stage to another but
rather afterwards. Therefore, the currently available proteomics
data sets that enabled the differential comparison of life cycle
changes, although highly useful, many not have accurately
captured all the dynamic perturbations in the proteome
occurring at the actual timescale of the differentiation process.
Additionally, the protein expression difference is not the only
parameter that determines protein function. Rather, a large
repertoire of protein modifications including PTMs and
changes in the activity of enzymes and dynamic changes in the
subcellular localisation of proteins during these processes must
be playing important roles. Some progress in this direction has
already been accomplished thanks to the recent developments
in PTM enrichment strategies and advancements in MS
instrumentation. For instance, large-scale profiling of important
post- and/or co-translational modifications such as
phosphorylation, glycosylation, N-terminal myristoylation and
SUMOylation was carried out in the protozoans. Some of the
enzymes responsible for these modifications have already been
validated as therapeutic targets. Accurate profiling of the target
engagement and off-target profiling of pharmacologically active
compounds as well as elucidating their mechanisms of action is
another stronghold of proteomics MS. A relatively new area
termed chemical proteomics that uses a combination of
synthetic chemistry tools and quantitative proteomics MS
technologies has evolved towards this end. This review has
touched upon recent developments in all these areas where
proteomics has played important roles.
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